Published online Aug 31, 2011.
https://doi.org/10.5534/kja.2011.29.2.161
The Effect of 5-alpha Reductase Inhibitors on the Efficacy of Photoselective Vaporization of the Prostate with 120 W GreenLight HPS Laser
Abstract
Purpose
To evaluate the effect of preoperative 5-alpha reductase inhibitor (ARI) administration on the operative results of photoselective vaporization of prostate with 120W GreenLight HPS laser.
Materials and Methods
Data were collected from 98 benign prostatic hyperplasia (BPH) patients who underwent transurethral electrovaporization of prostate by 120W Greenlight HPS laser between Jan. 2010 and Dec. 2010. We compared the time of operation, the energy required in lasering, postoperative maximum uroflow velocity, change in residual urine volume and complications between 5-ARI administrating group and control group.
Results
56 patients administrated 5-ARI at least 3 months before surgery. 30 and 26 patients administrated finasteride and dutasteride, respectively. Mean follow up period was 4.1±1.8 months. Mean age of the subjects and mean prostate volume were not different. Mean change of postoperative hemoglobin, lasing time and energy required in lasering were greater in 5-ARI administrating group. There were 3 and 1 cases of acute urinary retension in 5-ARI administrating group and control group, respectively.
Conclusions
The mean change of hemoglobin and mean energy required in lasering were greater and mean lasing time was longer in the patients who administrated 5-ARI before photoselective vaporization of prostate by 120W Greenlight HPS laser. Further investigation and extensive study will be needed to confirm these results.
Table 1
Preoperative characteristics of the 98 patients
Table 2
Operative end point and postoperative outcomes of the 98 patients
Table 3
Comparison of preoperative characteristics between finasteride and dutasteride group
Table 4
Comparison of operative end point and postoperative outcomes between finasteride and dutasteride group
References
-
Choo SH, Han DH, Lee SW. The efficacy and safety of KTP photoselective vaporization of the prostate for the treatment of benign prostatic hyperplasia: the 2-year results. Korean J Urol 2008;49:831–836.
-
-
Ko DW, Jeong BC, Son H. Initial experiences with a new 120 W greenlight(TM) high-power system for photoselective vaporization of the prostate for the treatment of benign prostatic hyperplasia in Korea. Korean J Urol 2009;50:1089–1094.
-
-
Choi HR, Chung WS, Shim BS, Kwon SW, Hong SJ, Chung BH, et al. Translation validity and reliability of I-PSS Korean version. Korean J Urol 1996;37:659–665.
-
-
Hwang EC, Joo JS, Min KD, Oh BR, Kang TW, Kwon DD, et al. A short-term comparative study on efficacy and safety of standard transurethral resection and high power (80W) potassium-titanyl-phosphate laser vaporization of the prostate. Korean J Urol 2005;46:1251–1255.
-
-
Park JS, Min GE, You CH, Hong B, Kim CS, Ahn H, et al. Comparison of treatment outcomes between photoselective vaporization and transurethral resection of the prostate for benign prostatic hyperplasia. Korean J Urol 2007;48:297–303.
-
-
Hwang EC, Joo JS, Min KD, Oh BR, Kang TW, Kwon DD, et al. A short-term comparative study on efficacy and safety of standard transurethral resection and high power (80W) potassium-titanyl-phosphate laser vaporization of the prostate. Korean J Urol 2005;46:1251–1255.
-
-
Cha WH, Jang TJ, Lee KS. Expression of Survivin and Bcl-2 in Benign Prostatic Hyperplasia Treated with a 5-alpha-reductase Inhibitor. Korean J Urol 2008;49:242–247.
-
-
Huynh H, Seyam RM, Brock GB. Reduction of ventral prostate weight by finasteride is associated with suppression of insulin-like growth factor I (IGF-I) and IGF-I receptor genes and with an increase in IGF binding protein 3. Cancer Res 1998;58:215–218.
-
-
Marihart S, Harik M, Djavan B. Dutasteride: a review of current data on a novel dual inhibitor of 5alpha reductase. Rev Urol 2005;7:203–210.
-
-
Pareek G, Shevchuk M, Armenakas NA, Vasjovic L, Hochberg DA, Basillote JB, et al. The effect of finasteride on the expression of vascular endothelial growth factor and microvessel density: a possible mechanism for decreased prostatic bleeding in treated patients. J Urol 2003;169:20–23.
-